Abstract:IntroductionIncreasing rates of multi-resistant bacteria are a major problem in the treatment of critically ill patients. Furthermore, conventional antibiotics lead to the release of bacterial derived membrane parts initiating pro-inflammatory cascades with potential harm to the patient. Antimicrobial peptides (AMP) may kill bacteria without releasing pro-inflammatory factors. Thus, we compared three newly developed synthetic anti-lipopolysaccharide peptides (SALPs) with a broader range of efficacy to suppress cytokine release in plasma and CD14 mRNA expression in organ tissue in a murine, polymicrobial sepsis model.MethodsA randomized, experimental trial was conducted in an animal research facility. Male NMRI mice (n = 90; 8- to 12-weeks old) were randomized to the following six groups: (i) sham operation and parenteral vehicle (NaCl 0.9%) administration (sham); (ii) cecal ligation and puncture (CLP) and vehicle infusion (sepsis-control), (iii) CLP and polymyxin B infusion (polyB), or (iv to vi) CLP and infusion of three different synthetic antimicrobial peptides Peptide 19-2.5 (Pep2.5), Peptide 19-4 (Pep4) or Peptide 19-8 (Pep8). All animals underwent arterial and venous catheterization for hemodynamic monitoring 48 hours prior to CLP or sham-operation. Physical appearance and behavior (activity), plasma cytokine levels, and CD14 mRNA expression in heart, lung, liver, spleen and kidney tissue were determined 24 hours after CLP or sham operation.ResultsOnly Pep2.5 significantly enhanced the activity after CLP, whereas none of the therapeutic regimens elevated the mean arterial pressure or heart rate. The strongly elevated IL-6, IL-10 and monocyte chemoattractant protein serum levels in septic animals were significantly reduced after Pep2.5 administration (P < 0.001, P < 0.001, and P < 0.001, respectively). Similarly, Pep2.5 significantly reduced the sepsis-induced CD14 mRNA expression in heart (P = 0.003), lung (P = 0.008), and spleen tissue (P = 0.009) but not in kidney and liver.ConclusionsStructurally variable SALPs exhibit major differences in their anti-inflammatory effect in vivo. Continuous parenteral administration of Pep2.5 is able to reduce sepsis-induced cytokine release and tissue inflammation.

Antimicrobial peptide 2K4L inhibits the inflammatory response in macrophages and Caenorhabditis elegans and protects against LPS-induced septic shock in mice

Antimicrobial peptide 2K4L disrupts the membrane of multidrug-resistant Acinetobacter baumannii and protects mice against sepsis

Tetrastigma Hemsleyanum Tubers Polysaccharide Ameliorates LPS-induced Inflammation in Macrophages and Caenorhabditis Elegans.

Potential role of a series of lysine-/leucine-rich antimicrobial peptide in inhibiting lipopolysaccharide-induced inflammation.

Cathelicidin-WA attenuates LPS-induced inflammation and redox imbalance through activation of AMPK signaling.

Turing cationic antimicrobial peptide KR-12 into Self-assembled nanobiotics with potent bacterial killing and LPS neutralizing activities

Α-Mangostin Suppresses NLRP3 Inflammasome Activation Via Promoting Autophagy in LPS-stimulated Murine Macrophages and Protects Against CLP-induced Sepsis in Mice

Transient Receptor Potential Melastatin 2 Protects Mice Against Polymicrobial Sepsis by Enhancing Bacterial Clearance (INC6P.342)

The Antimicrobial Peptide Chensinin-1B Alleviates the Inflammatory Response by Targeting the TLR4/NF-κB Signaling Pathway and Inhibits Pseudomonas Aeruginosa Infection and LPS-mediated Sepsis.

Awrk6, A Synthetic Cationic Peptide Derived From Antimicrobial Peptide Dybowskin-2cdya, Inhibits Lipopolysaccharide-Induced Inflammatory Response

LECT2 Protects Mice Against Bacterial Sepsis by Activating Macrophages Via the CD209a Receptor.

Protective Effect of Ginsenosides Rg1 and Re on Lipopolysaccharide-Induced Sepsis by Competitive Binding to Toll-like Receptor 4.

Lipocalin-2 Alleviates LPS-Induced Inflammation Through Alteration of Macrophage Properties

Dipyrithione Inhibits Lipopolysaccharide-Induced Inos and Cox-2 Up-Regulation in Macrophages and Protects Against Endotoxic Shock in Mice

Antimicrobial Peptide CATH-2 Attenuates Avian Pathogenic E. Coli-Induced Inflammatory Response Via NF-κB/NLRP3/MAPK Pathway and Lysosomal Dysfunction in Macrophages

Tree Frog-Derived Cathelicidin Protects Mice against Bacterial Infection through Its Antimicrobial and Anti-Inflammatory Activities and Regulatory Effect on Phagocytes

The anti-inflammatory effect of the synthetic antimicrobial peptide 19-2.5 in a murine sepsis model: a prospective randomized study

Lipopolysaccharide neutralization by the antibacterial peptide CM4.

ZL-2, a Cathelicidin-Derived Antimicrobial Peptide, Has a Broad Antimicrobial Activity Against Gram-Positive Bacteria and Gram-Negative Bacteria in Vitro and in Vivo

Lobetyolin protects mice against LPS-induced sepsis by downregulating the production of inflammatory cytokines in macrophage

A Novel Small Molecule, HK-156, Inhibits Lipopolysaccharide-Induced Activation of NF-κB Signaling and Improves Survival in Mouse Models of Sepsis